AbbVie Inc. Operating Income Loss

• AbbVie Inc. showed an increase of +65.0% in Operating Income Loss from 2024 to 2025.
• This data is from AbbVie Inc.'s annual report (Form 10-K), filed with the SEC on February 20, 2026.
• XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 15 years of available data (2011 to 2025), AbbVie Inc.'s Operating Income Loss has grown by 316.4%.
• Historical annual values: Fiscal year 2025: $15.08 billion | Fiscal year 2024: $9.14 billion | Fiscal year 2023: $12.76 billion | Fiscal year 2022: $18.12 billion | Fiscal year 2021: $17.92 billion | Fiscal year 2020: $11.36 billion | Fiscal year 2019: $12.98 billion | Fiscal year 2018: $6.38 billion | Fiscal year 2017: $9.55 billion | Fiscal year 2016: $9.34 billion | Fiscal year 2015: $7.54 billion | Fiscal year 2014: $3.41 billion | Fiscal year 2013: $5.66 billion | Fiscal year 2012: $5.82 billion | Fiscal year 2011: $3.62 billion.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026